Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference
John H. Beigel, Hannah Nam, Peter L. Adams, et al.
Antiviral Research (2019) Vol. 167, pp. 45-67
Open Access | Times Cited: 166

Showing 1-25 of 166 citing articles:

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
Waleed Alhazzani, Morten Hylander Møller, Yaseen M. Arabi, et al.
Intensive Care Medicine (2020) Vol. 46, Iss. 5, pp. 854-887
Open Access | Times Cited: 2009
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, et al.
The Lancet (2020) Vol. 395, Iss. 10238, pp. 1695-1704
Open Access | Times Cited: 1488
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
Waleed Alhazzani, Morten Hylander Møller, Yaseen M. Arabi, et al.
Critical Care Medicine (2020) Vol. 48, Iss. 6, pp. e440-e469
Open Access | Times Cited: 1362
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
David Gurwitz
Drug Development Research (2020) Vol. 81, Iss. 5, pp. 537-540
Open Access | Times Cited: 823
COVID-19: Immunology and treatment options
Susanna Felsenstein, Jenny A. Herbert, Paul McNamara, et al.
Clinical Immunology (2020) Vol. 215, pp. 108448-108448
Open Access | Times Cited: 657
Treatment options for COVID-19: The reality and challenges
Shio-Shin Jean, Ping‐Ing Lee, Po‐Ren Hsueh
Journal of Microbiology Immunology and Infection (2020) Vol. 53, Iss. 3, pp. 436-443
Open Access | Times Cited: 516
Middle East respiratory syndrome
Ziad A. Memish, Stanley Perlman, Maria D. Van Kerkhove, et al.
The Lancet (2020) Vol. 395, Iss. 10229, pp. 1063-1077
Open Access | Times Cited: 453
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Miguel Ángel Martı́nez
Antimicrobial Agents and Chemotherapy (2020) Vol. 64, Iss. 5
Open Access | Times Cited: 449
Reducing mortality from 2019-nCoV: host-directed therapies should be an option
Alimuddin Zumla, David S.C. Hui, Esam I. Azhar, et al.
The Lancet (2020) Vol. 395, Iss. 10224, pp. e35-e36
Open Access | Times Cited: 444
Respiratory syncytial virus infection in adults
Hannah Nam, Michael G. Ison
BMJ (2019), pp. l5021-l5021
Closed Access | Times Cited: 245
Critical care management of adults with community-acquired severe respiratory viral infection
Yaseen M. Arabi, Robert Fowler, Frederick G. Hayden
Intensive Care Medicine (2020) Vol. 46, Iss. 2, pp. 315-328
Open Access | Times Cited: 240
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic
Lei Tian, Taotao Qiang, Chengyuan Liang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 213, pp. 113201-113201
Open Access | Times Cited: 173
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
Xiaoxuan Zhao, Yuepeng Jiang, Yang Zhao, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2020) Vol. 39, Iss. 7, pp. 1209-1220
Open Access | Times Cited: 166
Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection
Yeming Wang, Guohui Fan, Alex P. Salam, et al.
The Journal of Infectious Diseases (2019) Vol. 221, Iss. 10, pp. 1688-1698
Open Access | Times Cited: 148
Therapeutic strategies for critically ill patients with COVID-19
Lei Li, Ranran Li, Zhixiong Wu, et al.
Annals of Intensive Care (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 135
Involvement of the Nervous System in SARS-CoV-2 Infection
Hao Li, Qun Xue, Xingshun Xu
Neurotoxicity Research (2020) Vol. 38, Iss. 1, pp. 1-7
Open Access | Times Cited: 127
Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial
John H. Beigel, Evgenia Aga, Marie‐Carmelle Elie‐Turenne, et al.
The Lancet Respiratory Medicine (2019) Vol. 7, Iss. 11, pp. 941-950
Open Access | Times Cited: 100
Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19)
Muhammad Shahid Nadeem, Mazin A. Zamzami, Hani Choudhry, et al.
Pathogens (2020) Vol. 9, Iss. 4, pp. 307-307
Open Access | Times Cited: 95
SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
Denisa Bojková, Jake E McGreig, Katie-May McLaughlin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 89
An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19)
Arunodaya Raj Mishra, Pratibha Rani, R. Krishankumar, et al.
Applied Soft Computing (2021) Vol. 103, pp. 107155-107155
Open Access | Times Cited: 89
In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
Johanna Signer, Hulda R. Jónsdóttir, Werner C. Albrich, et al.
Virology Journal (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 79
Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19
Chao-Ping Wu, Fatima Adhi, Kristin B. Highland
Cleveland Clinic Journal of Medicine (2020) Vol. 87, Iss. 11, pp. 659-663
Open Access | Times Cited: 72
nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics
Md. Tanvir Kabir, Md. Sahab Uddin, Md. Farhad Hossain, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 72
Exploring the Binding Efficacy of Ivermectin Against the Key Proteins of SARS-CoV-2 Pathogenesis: an in silico Approach
Abhigyan Choudhury, Nabarun Chandra Das, Ritwik Patra, et al.
Future Virology (2021) Vol. 16, Iss. 4, pp. 277-291
Open Access | Times Cited: 69
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top